Methyl aminolevulinate for the treatment of: thin or non-hyperkeratotic and non-pigmented actinic keratoses on the face and scalp, when other therapies are considered less appropriate; superficial and/or nodular basal cell carcinoma unsuitable for other available therapies; and squamous cell carcinoma in situ (Bowen´s disease) when surgical excision is considered less appropriate.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||06/11/2019|
|Rapid review completed||18/12/2019|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that methyl aminolevulinate (Metvix®) not be considered for reimbursement at the submitted price*.|
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.